The Rodenstock Group, a global leader in eye health innovation and manufacturer of biometric, ophthalmic lenses, has reached an agreement to sell its eyewear business to De Rigo, a family-owned global market leader in the design, production, and distribution of high-quality eyewear. The transaction is expected to be completed towards the end of second quarter of 2023.
Rodenstock has been a global leader in prescription lenses for over 140 years, with a strong track record of innovative product development. With the introduction of B.I.G. VISION™ for all in 2020 and the launch of its B.I.G. NORM™ technology in early 2022, Rodenstock reinforced its capabilities in developing market leading technologies and setting benchmarks in the industry.
Having carefully examined different options, the Rodenstock management is taking the strategic decision to sell the eyewear business, thereby achieving another major step on its transformational path to become a leading Med-Tech company in vision care. Rodenstock will continue to invest in its R&D capabilities as well as product and service portfolio to best meet its customer’s needs, and further strengthen its leadership position in biometric lenses.
Rodenstock and De Rigo are trusted, long-standing business partners sharing a unique promise of quality and a strong heritage as family businesses. De Rigo is ideally positioned to further drive the development of the eyewear business and strengthen its brands Rodenstock Eyewear and Porsche Design Eyewear. Both companies will closely work together to ensure a smooth transition and business continuity for employees, customers, and business partners.